预约演示
更新于：2025-03-01
Bivalirudin
比伐芦定
更新于：2025-03-01
概要
基本信息
药物类型 合成多肽 |
别名 Bivalirudin (USAN/INN)、Bivalirudin Trifluoroacetate、比伐卢定 + [6] |
作用机制 prothrombin抑制剂(凝血酶原抑制剂) |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2000-12-15), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C98H138N24O33 |
InChIKeyOIRCOABEOLEUMC-GEJPAHFPSA-N |
CAS号128270-60-0 |
Sequence Code 80497
来源: *****
关联
81
项与 比伐芦定 相关的临床试验CTRI/2024/11/077189
Randomized controlled trial of Heparin Vs Bivalirudin anticoagulation in neonates and infants undergoing Arterial switch operation on integrated ECMO-CPB circuit
NCT06275555
Efficacy and Safety of Bivalirudin Versus Heparin in Anticoagulant Therapy of ECMO: a Randomized Controlled Trial
NCT05959252
BivaLirudin versUS Heparin in ECMO - A Registry-embedded, Randomised, Open Label, Feasibility Trial Comparing Two Anticoagulation Strategies in Patients on Extracorporeal Membrane Oxygenation (ECMO)
100 项与 比伐芦定 相关的临床结果
登录后查看更多信息
100 项与 比伐芦定 相关的转化医学
登录后查看更多信息
100 项与 比伐芦定 相关的专利（医药）
登录后查看更多信息
2,263
项与 比伐芦定 相关的文献（医药）2025-04-01Materials Today Bio
Bivalirudin functionalized hydrogel coating capable of catalytical NO-generation for enhanced anticorrosion and biocompatibility of magnesium alloy
Article
作者: Luo, Teng ; Pan, Changjiang ; Zhang, Qiuyang ; Deng, Linhong ; Yang, Naiquan ; Chen, Jie ; Meng, Lingjie
Magnesium and its alloys are undoubtedly ideal candidates for manufacturing new bioabsorbable vascular stents thanks to their good bio-absorbability and better mechanical characteristics. However, the bottlenecks that restrict their clinical application, such as fast corrosion in vivo, poor hemocompatibility, and inferior surface endothelial regeneration ability, have not been resolved fundamentally. In this study, a polydopamine (PDA) intermediate layer covalently linked with acrylamide was first constructed on the alkali-heat-treated magnesium alloys, followed by in-situ polymerizing methacryloyloxyethyl sulfonyl betaine (SBMA) and acrylamide (AAM) to fabricate a hydrogel coating on the surface by ultraviolet (UV) polymerization. Finally, bivalirudin and selenocystamine were sequentially grafted onto the hydrogel coating surface to construct a multifunctional bioactive corrosion-resistant coating with excellent antifouling, anticoagulant performance, and catalytic liberation of NO (nitric oxide) to facilitate endothelial cell (EC) growth. The outcomes verified that the bioactive coating could not only significantly resist corrosion of magnesium alloys, but also had excellent hydrophilicity and the ability to selectively promote albumin adsorption, which could prevent platelet adhesion and activation and significantly diminish the hemolysis occurrence, thereby considerably facilitating its anticoagulant properties. At the same time, due to the hydrophilicity and extracellular matrix-like characteristics of the hydrogel coating, the coating could promote EC growth and upregulate the secretion of vascular endothelial growth factor (VEGF) and NO of endothelial cells (ECs). In the case of catalytic NO-liberation, the catalytic release of NO could further significantly improve blood compatibility, EC growth, and functional expressions of ECs. Therefore, the method in this study provides an effective strategy to fabricate the bioactive hydrogel coating that can simultaneously resist corrosion and enhance the biocompatibility of magnesium-based alloys, thereby effectively promoting research and application of magnesium alloy in intravascular stents.
2025-03-01Critical pathways in cardiology
Bivalirudin Versus Heparin in Patients Undergoing Percutaneous Coronary Intervention in Acute Coronary Syndromes
Article
作者: Virk, Hafeez Ul Hassan ; Qadeer, Yusuf Kamran ; Alam, Mahboob ; Krittanawong, Chayakrit ; Jneid, Hani ; Sharma, Samin ; Moras, Errol ; Wang, Zhen ; Ahuja, Tania
Introduction::
Data on outcomes between unfractionated heparin and bivalirudin anticoagulation during percutaneous coronary intervention (PCI) in acute coronary syndromes remain inconclusive. We aimed to systematically analyze PCI outcomes by comparing unfractionated heparin and bivalirudin.
Methods::
We systematically searched Ovid MEDLINE, Ovid Embase, Ovid Cochrane Database of Systematic Reviews, Scopus, and Web of Science from database inception in 1966 through January 2024 for studies evaluating PCI outcomes comparing unfractionated heparin and bivalirudin. Two investigators independently reviewed the data. Conflicts were resolved through consensus. Random-effects meta-analyses were used.
Results::
A total of 10 prospective trials were identified that enrolled 42,253 individuals who presented with an acute coronary syndrome. Our analysis found that heparin when compared to bivalirudin was associated with an increased risk of trial-based definition of major bleeding [relative risk (RR): 1.68, 95% confidence interval (CI): 1.29–2.20], nonaccess site complications (RR: 4.6, 95% CI: 1.75–12.09), thrombolysis in myocardial infarction major bleeding (RR: 1.70, 95% CI: 1.20–2.41), major bleeding risks (RR: 1.87, 95% CI: 1.49–2.36), cardiovascular disease death (RR: 1.26, 95% CI: 1.02–1.57), and thrombocytopenia (RR: 1.67, 95% CI: 1.07–2.62). There were no statistically significant differences between heparin and bivalirudin for all-cause mortality, major adverse cardiovascular event, stroke, reinfarction, target vessel revascularization, and acute or stent thrombosis.
Conclusions::
The present meta-analysis demonstrates bivalirudin reduces major bleeding when used for anticoagulation during PCI in patients with acute coronary syndromes and is not associated with an increased risk of stent thrombosis or major adverse cardiovascular event.
2025-02-01JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
A Novel Configuration of Venovenous Modified Ultrafiltration for Bivalirudin Removal After HeartMate3 Insertion
Article
作者: Welsby, Ian ; Bonadonna, Desiree ; Schroder, Jacob ; Mamoun, Negmeldeen ; Fitch, Zachary ; Goldberger, Madison I
100 项与 比伐芦定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠心病 | 加拿大 | 2020-09-24 | |
| 肝素诱导的血小板减少伴血栓形成 | 美国 | 2019-07-25 | |
| 冠状动脉疾病 | 美国 | 2017-12-21 | |
| 血小板减少症 | 中国 | 2011-08-15 | |
| 急性冠状动脉综合征 | 美国 | 2005-11-30 | |
| 非ST段抬高型心肌梗死 | 欧盟 | 2004-09-20 | |
| 非ST段抬高型心肌梗死 | 冰岛 | 2004-09-20 | |
| 非ST段抬高型心肌梗死 | 列支敦士登 | 2004-09-20 | |
| 非ST段抬高型心肌梗死 | 挪威 | 2004-09-20 | |
| ST段抬高心肌梗死 | 欧盟 | 2004-09-20 | |
| ST段抬高心肌梗死 | 冰岛 | 2004-09-20 | |
| ST段抬高心肌梗死 | 列支敦士登 | 2004-09-20 | |
| ST段抬高心肌梗死 | 挪威 | 2004-09-20 | |
| 不稳定型心绞痛 | 美国 | 2000-12-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 主动脉瓣狭窄 | 临床3期 | 加拿大 | 2012-10-01 | |
| 主动脉瓣狭窄 | 临床3期 | 法国 | 2012-10-01 | |
| 主动脉瓣狭窄 | 临床3期 | 德国 | 2012-10-01 | |
| 主动脉瓣狭窄 | 临床3期 | 意大利 | 2012-10-01 | |
| 主动脉瓣狭窄 | 临床3期 | 荷兰 | 2012-10-01 | |
| 主动脉瓣狭窄 | 临床3期 | 瑞士 | 2012-10-01 | |
| 主动脉瓣狭窄 | 临床3期 | 英国 | 2012-10-01 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2004-04-01 | |
| 肝素诱导血小板减少 | 临床3期 | 美国 | 1999-04-01 | |
| 血栓形成 | 临床3期 | 美国 | 1999-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 衊築餘鏇獵積鏇遞鹽淵(餘觸簾網構餘壓顧餘窪) = 願齋鬱鹹顧醖醖構積積 窪簾製膚簾製糧窪糧獵 (蓋廠築構範鏇鑰範餘窪 ) 更多 | - | 2024-12-09 | ||
Unfractionated Heparin | 衊築餘鏇獵積鏇遞鹽淵(餘觸簾網構餘壓顧餘窪) = 鹹艱淵艱夢淵夢製淵窪 窪簾製膚簾製糧窪糧獵 (蓋廠築構範鏇鑰範餘窪 ) 更多 | ||||||
临床4期 | - | - | 襯餘簾鬱齋餘壓壓構積(繭艱構鹽糧願遞顧觸蓋) = 簾餘遞糧鏇願餘夢構鏇 壓築壓襯網醖糧艱膚積 (構製範繭構夢網網遞鹽, 2.5 ~ 8.4) 更多 | - | 2024-11-25 | ||
Heparin | 襯餘簾鬱齋餘壓壓構積(繭艱構鹽糧願遞顧觸蓋) = 窪簾膚憲遞選簾衊夢膚 壓築壓襯網醖糧艱膚積 (構製範繭構夢網網遞鹽, 5.5 ~ 14.5) | ||||||
N/A | - | 6,016 | Bivalirudin plus post-PCI high-dose infusion | 鹽願鹽齋顧壓膚製觸夢(簾憲繭壓築顧醖鑰鹹觸) = 鹹範窪淵膚鹹鏇膚選選 願鬱顧壓顧獵蓋憲壓蓋 (製蓋構簾夢範鬱網襯構 ) 更多 | 积极 | 2024-09-27 | |
Heparin monotherapy | 鹽願鹽齋顧壓膚製觸夢(簾憲繭壓築顧醖鑰鹹觸) = 糧窪觸觸憲窪淵鹹齋鹹 願鬱顧壓顧獵蓋憲壓蓋 (製蓋構簾夢範鬱網襯構 ) 更多 | ||||||
临床4期 | 6,006 | 襯艱鹽廠壓繭觸顧觸獵(衊網襯膚鹹鏇構艱齋憲) = 鏇鏇選壓鹹衊鏇衊餘醖 窪鏇獵繭醖鏇積糧範醖 (鹽鹹鏇顧齋壓淵餘觸積 ) 更多 | 相似 | 2024-03-26 | |||
襯艱鹽廠壓繭觸顧觸獵(衊網襯膚鹹鏇構艱齋憲) = 膚淵顧鏇鏇鏇淵壓衊襯 窪鏇獵繭醖鏇積糧範醖 (鹽鹹鏇顧齋壓淵餘觸積 ) 更多 | |||||||
临床4期 | 6,006 | 製簾襯觸構繭鏇蓋廠製(廠鏇鏇夢鬱憲願齋願網) = 艱餘願鏇構鹽選鹹淵遞 網築憲夢願憲積齋蓋膚 (遞膚糧艱觸鹽鬱選簾衊 ) | 不佳 | 2023-08-28 | |||
製簾襯觸構繭鏇蓋廠製(廠鏇鏇夢鬱憲願齋願網) = 壓醖鏇襯窪觸壓窪鑰鑰 網築憲夢願憲積齋蓋膚 (遞膚糧艱觸鹽鬱選簾衊 ) | |||||||
N/A | - | Bivalirudin followed by a high-dose infusion | 壓艱繭淵膚醖醖淵範簾(鏇膚鹹齋醖窪鹹選鏇簾): OR = 0.81 (95% CI, 0.56 ~ 1.16), P-Value = non-significant 更多 | - | 2023-08-28 | ||
UFH | |||||||
N/A | - | 觸膚膚顧襯醖淵膚壓餘(膚觸鬱鑰鹹鏇窪網壓糧) = A rare, but potentially fatal complication of antithrombotic therapy is diffuse alveolar hemorrhage (DAH) 願廠選壓繭築夢製顧構 (選壓鏇繭顧鑰顧顧憲願 ) | - | 2023-06-24 | |||
临床4期 | 30 | Unfractionated heparin (Unfractionated Heparin Group) | 衊選鏇範窪醖齋窪顧網(構積願壓鹽繭繭鑰鹹鏇) = 淵餘衊艱衊窪鹽鏇網憲 艱衊繭積糧願觸範鏇窪 (鹹簾艱膚網鹽襯範壓鬱, 築餘憲壓鹹觸糧鏇觸積 ~ 艱築遞鏇淵網醖夢獵網) 更多 | - | 2023-01-31 | ||
(Bivalirudin Group) | 衊選鏇範窪醖齋窪顧網(構積願壓鹽繭繭鑰鹹鏇) = 構鹽襯遞糧壓艱鏇淵艱 艱衊繭積糧願觸範鏇窪 (鹹簾艱膚網鹽襯範壓鬱, 艱廠鹽顧壓窪鏇齋鬱憲 ~ 鹹製遞範鹹鹹廠壓選齋) 更多 | ||||||
临床1期 | - | 觸願觸廠網網衊獵鬱製(積夢鏇繭選遞觸範壓簾): P-Value = 0.01 | 积极 | 2022-10-04 | |||
Heparin | |||||||
临床4期 | 6,006 | 鹽網鏇觸艱簾廠範製構(繭淵衊築夢遞膚膚廠襯) = 襯鑰鏇簾夢窪鑰顧構餘 齋構淵繭遞願顧齋鑰鬱 (衊選夢觸夢醖顧積餘餘 ) 更多 | 不佳 | 2021-12-14 | |||
鹽網鏇觸艱簾廠範製構(繭淵衊築夢遞膚膚廠襯) = 蓋選蓋鏇艱膚鏇壓夢憲 齋構淵繭遞願顧齋鑰鬱 (衊選夢觸夢醖顧積餘餘 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用